Targeting splicing abnormalities in cancer.

Abstract excerpt

Recently splicing has been recognized as a key pathway in cancer. Although aberrant splicing has been shown to be a consequence of mutations or the abnormal expression of splicing factors (trans-effect changes) or mutations in the splicing sequences (cis-effect mutations), the connections between aberrant splicing and cancer initiation or progression are still not well understood. Here we review the mutational...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Neoplasms
• Share to Oligonucleotides